%0 Journal Article
%T 68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
%A Isabel Rauscher
%A Markus Schwaiger
%A Matthias Eiber
%A Tobias Maurer
%A Wieland H. Sommer
%A Wolfgang P. Fendler
%J Archive of "Cancer Imaging".
%D 2016
%R 10.1186/s40644-016-0072-6
%X Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate cancer and restaging after biochemical recurrence with 68Ga-PSMA ligand Positron emission tomography/computed tomography (PET/CT). However, prospective trials and clinical guidelines for this new technique are still missing. Therefore, we summarized our experience with 68Ga-PSMA ligand PET/CT examinations in patients with primary PC and biochemical recurrence. It focuses on the technical and logistical aspects of 68Ga-PSMA ligand PET/CT examination as well as on the specific background for image reading discussing also potential pitfalls. Further, it includes relevant issues on free-text as well as structured reporting used in daily clinical routine
%K Prostate cancer
%K Prostate specific membrane antigen
%K Positron emission tomography
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898465/